Kropp & själ
Pocket
Pentamycin - a new option for the treatment of infections with Trichomonas vaginalis?
Markus Kranzler
1749:-
Uppskattad leveranstid 5-10 arbetsdagar
Fri frakt för medlemmar vid köp för minst 249:-
Diplomarbeit aus dem Jahr 2011 im Fachbereich Biologie - Mikrobiologie, Molekularbiologie, Note: 1, Universitt Wien, Sprache: Deutsch, Abstract: The protozoan parasite Trichomonas vaginalis is the causative agent of trichomonosis
which is - with more than 170 million new cases each year - the most prevalent
non-viral sexually transmitted disease (STD) worldwide. Although trichomonosis is
not a primarily lethal disease, the clinical picture can include severe urogenital
inflammations. Chronic infections have been associated with cervical/prostate cancer
and a predisposition of HIV infections. In case of pregnancy, chronic infections can
also lead to preterm delivery and low birth weight. For more than 50 years,
metronidazole, a nitroimidazole antibiotic, has been in use for the treatment of
trichomonosis. It is applied orally and although it is mostly compliant, it can have
serious side effects. It is also not applicable for pregnant women due to its ability to
pass the placenta. Furthermore, an increasing number of emerging metronidazoleresistant
T. vaginalis strains has lead to more treatment failures in the last few years.
To this day, however, there is no effective alternative drug against trichomonosis
available.
Pentamycin is a polyene antimycotic and has been in use in the treatment of
candidiasis, in preliminary studies it also turned out to be effective against
trichomonads.
The aim of this study was to evaluate the efficacy of pentamycin against T. vaginalis
and the ability to develop resistances in vitro. For these purposes, the dose-effect
relationship between pentamycin and four differently metronidazole-sensitive T.
vaginalis strains was investigated. Moreover, the protein composition before and after
the treatment was compared. To induce resistance, strains were treated with
sublethal concentrations of pentamycin within a time of six months.
It could be shown that pentamycin is highly effective against T. vaginalis. A 100%
eradication of trichomonads
which is - with more than 170 million new cases each year - the most prevalent
non-viral sexually transmitted disease (STD) worldwide. Although trichomonosis is
not a primarily lethal disease, the clinical picture can include severe urogenital
inflammations. Chronic infections have been associated with cervical/prostate cancer
and a predisposition of HIV infections. In case of pregnancy, chronic infections can
also lead to preterm delivery and low birth weight. For more than 50 years,
metronidazole, a nitroimidazole antibiotic, has been in use for the treatment of
trichomonosis. It is applied orally and although it is mostly compliant, it can have
serious side effects. It is also not applicable for pregnant women due to its ability to
pass the placenta. Furthermore, an increasing number of emerging metronidazoleresistant
T. vaginalis strains has lead to more treatment failures in the last few years.
To this day, however, there is no effective alternative drug against trichomonosis
available.
Pentamycin is a polyene antimycotic and has been in use in the treatment of
candidiasis, in preliminary studies it also turned out to be effective against
trichomonads.
The aim of this study was to evaluate the efficacy of pentamycin against T. vaginalis
and the ability to develop resistances in vitro. For these purposes, the dose-effect
relationship between pentamycin and four differently metronidazole-sensitive T.
vaginalis strains was investigated. Moreover, the protein composition before and after
the treatment was compared. To induce resistance, strains were treated with
sublethal concentrations of pentamycin within a time of six months.
It could be shown that pentamycin is highly effective against T. vaginalis. A 100%
eradication of trichomonads
- Format: Pocket/Paperback
- ISBN: 9783656145516
- Språk: Engelska
- Antal sidor: 190
- Utgivningsdatum: 2012-03-06
- Förlag: Grin Verlag